Your browser doesn't support javascript.
loading
Immuno-regulatory malignant B cells contribute to Chronic Lymphocytic Leukemia progression.
Mékinian, Arsène; Quinquenel, Anne; Belkacem, Koceïla Ait; Kanoun, Feriel; Dondi, Elisabetta; Franck, Emilie; Boubaya, Marouane; Mhibik, Maïssa; Baran-Marszak, Fanny; Letestu, Rémi; Ajchenbaum-Cymbalista, Florence; Lévy, Vincent; Varin-Blank, Nadine; Le Roy, Christine.
Afiliación
  • Mékinian A; INSERM, U978, Bobigny, France.
  • Quinquenel A; Université Paris 13 dite « Sorbonne Paris Nord ¼, UFR SMBH, Labex INFLAMEX, Bobigny, France.
  • Belkacem KA; INSERM, U978, Bobigny, France.
  • Kanoun F; Université Paris 13 dite « Sorbonne Paris Nord ¼, UFR SMBH, Labex INFLAMEX, Bobigny, France.
  • Dondi E; INSERM, U978, Bobigny, France.
  • Franck E; Université Paris 13 dite « Sorbonne Paris Nord ¼, UFR SMBH, Labex INFLAMEX, Bobigny, France.
  • Boubaya M; INSERM, U978, Bobigny, France.
  • Mhibik M; Université Paris 13 dite « Sorbonne Paris Nord ¼, UFR SMBH, Labex INFLAMEX, Bobigny, France.
  • Baran-Marszak F; INSERM, U978, Bobigny, France.
  • Letestu R; Université Paris 13 dite « Sorbonne Paris Nord ¼, UFR SMBH, Labex INFLAMEX, Bobigny, France.
  • Ajchenbaum-Cymbalista F; INSERM, U978, Bobigny, France.
  • Lévy V; Université Paris 13 dite « Sorbonne Paris Nord ¼, UFR SMBH, Labex INFLAMEX, Bobigny, France.
  • Varin-Blank N; URC, APHP, Hôpital Avicenne, Bobigny, France.
  • Le Roy C; INSERM, U978, Bobigny, France.
Cancer Gene Ther ; 30(7): 1018-1028, 2023 07.
Article en En | MEDLINE | ID: mdl-36973425
ABSTRACT
Chronic Lymphocytic Leukemia (CLL) is a heterogeneous B cell neoplasm ranging from indolent to rapidly progressive disease. Leukemic cell subsets with regulatory properties evade immune clearance; however, the contribution of such subsets during CLL progression is not completely elucidated. Here, we report that CLL B cells crosstalk with their immune counterparts, notably by promoting the regulatory T (Treg) cell compartment and shaping several helper T (Th) subsets. Among various constitutively- and BCR/CD40-mediated factors secreted, tumour subsets co-express two important immunoregulatory cytokines, IL10 and TGFß1, both associated with a memory B cell phenotype. Neutralizing secreted IL10 or inhibiting the TGFß signalling pathway demonstrated that these cytokines are mainly involved in Th- and Treg differentiation/maintenance. In line with the regulatory subsets, we also demonstrated that a CLL B cell population expresses FOXP3, a marker of regulatory T cells. Analysis of IL10, TGFß1 and FOXP3 positive subpopulations frequencies in CLL samples discriminated 2 clusters of untreated CLL patients that were significantly different in Tregs frequency and time-to-treatment. Since this distinction was pertinent to disease progression, the regulatory profiling provides a new rationale for patient stratification and sheds light on immune dysfunction in CLL.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article